Vertex says telaprevir may cut down HCV treatment time

08/11/2010 | Google

Some hepatitis C patients who took drug candidate telaprevir were able to finish treatment sooner than with standard therapy, according to Vertex Pharmaceuticals. The company said patients in the clinical trial who responded quickly to telaprevir had better results after 24 weeks of therapy compared with 48 weeks.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC